You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 60 No. 6, June 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (41)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Depression
 •Suicide
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Occurrence and Course of Suicidality During Short-term Treatment of Late-Life Depression

Katalin Szanto, MD; Benoit H. Mulsant, MD; Patricia Houck, MSH; Mary Amanda Dew, PhD; Charles F. Reynolds III, MD

Arch Gen Psychiatry. 2003;60:610-617.

Background  Elderly persons (≥65 years) have the highest rate of suicide; still, little is known about the occurrence, course, and responsivity of suicidal ideation during treatment of depression in late life and how suicidality affects treatment response.

Methods  This study was undertaken to determine (1) how suicidal ideation changes during short-term depression treatment and (2) whether treatment response differs among 3 groups of patients based on their levels of suicidality at baseline and during treatment (those with a recent suicide attempt or current suicidal ideation [high-risk group; n = 46], those with recurrent thoughts of death [moderate-risk group; n = 143], or those with no suicide attempt, suicidal ideation, or thoughts of death [low-risk group; n = 206]). This is a secondary analysis of pooled data from 3 treatment studies of late-life major depression. Participants were 395 elderly persons with a current major depressive episode, treated as inpatients or outpatients under protocolized conditions with paroxetine hydrochloride or nortriptyline hydrochloride, with or without interpersonal psychotherapy. Changes in suicidal ideation over time, rate of responses, and time to response in each group were compared.

Results  Suicidal ideation decreased rapidly early in the course of treatment, with more gradual change thereafter. At the beginning of treatment, 77.5% of the patients reported suicidal ideation, thoughts of death, or feelings that life is empty. After 12 weeks of treatment, suicidal ideation had resolved in all treated patients; 4.6% still reported thoughts of death. However, 6-week (P = .001) and 12-week (P = .02) rates of response were significantly lower in high-risk patients than in low- and moderate-risk patients. High- and moderate-risk patients needed a significantly (P<.001) longer time to respond than low-risk patients (median time to response, 6 and 5 vs 3 weeks).

Conclusions  While suicidal ideation resolves rapidly, the resolution of thoughts about death is more gradual. Suicidal elderly persons with depression require special attention during depression treatment because they have a lower response rate and need a longer time to respond.


From the Department of Psychiatry, the Intervention Research Center for the Study of Late-Life Mood Disorders (Drs Szanto, Mulsant, Dew, and Reynolds and Ms Houck), and the Geriatric Research, Education and Clinical Center, VA Pittsburgh Healthcare System (Dr Mulsant), Pittsburgh, Pa. Dr Mulsant is now with the Western Psychiatric Institute and Clinic, Pittsburgh. Drs Mulsant and Reynolds have received honoraria and/or grant support from antidepressant manufacturers, including Bristol-Myers Squibb, Wallingford, Conn; Eli Lilly & Co, Indianapolis, Ind; Forest Pharmaceuticals Inc, St Louis, Mo; GlaxoSmithKline, Brentford, Middlesex, England; Pharmacia & Upjohn, Inc, Kalamazoo, Mich; Pfizer Inc, New York, NY; and Solvay Pharmaceuticals, Marietta, Ga.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Stemming the Tide of Suicide in Older White Men: A Call to Action
Schmutte et al.
Am J Mens Health 2009;3:189-200.
ABSTRACT  

Reducing Suicidal Ideation and Depression in Older Primary Care Patients: 24-Month Outcomes of the PROSPECT Study
Alexopoulos et al.
Am. J. Psychiatry 2009;166:882-890.
ABSTRACT | FULL TEXT  

Empirically Derived Decision Trees for the Treatment of Late-Life Depression
Andreescu et al.
Focus 2009;7:79-87.
ABSTRACT | FULL TEXT  

Empirically Derived Decision Trees for the Treatment of Late-Life Depression
Andreescu et al.
Am. J. Psychiatry 2008;165:855-862.
ABSTRACT | FULL TEXT  

Social Inequalities in Response to Antidepressant Treatment in Older Adults
Cohen et al.
Arch Gen Psychiatry 2006;63:50-56.
ABSTRACT | FULL TEXT  

Reducing Suicidal Ideation and Depressive Symptoms in Depressed Older Primary Care Patients: A Randomized Controlled Trial
Bruce et al.
JAMA 2004;291:1081-1091.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.